142 related articles for article (PubMed ID: 34387605)
21. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
22. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
[TBL] [Abstract][Full Text] [Related]
23. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
[TBL] [Abstract][Full Text] [Related]
24. A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy.
Bryk DJ; Angermeier KW; Klein EA
Urology; 2019 Jul; 129():e4-e5. PubMed ID: 30935936
[TBL] [Abstract][Full Text] [Related]
25. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
[No Abstract] [Full Text] [Related]
26. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
[No Abstract] [Full Text] [Related]
27. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
29. Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.
Akyol F; Selek U; Ozyigit G; Onal C; Akdogan B; Karabulut E; Ozen H
J Natl Med Assoc; 2006 Jul; 98(7):1058-61. PubMed ID: 16895273
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
Palmberg C; Koivisto P; Hyytinen E; Isola J; Visakorpi T; Kallioniemi OP; Tammela T
Eur Urol; 1997; 31(2):216-9. PubMed ID: 9076469
[TBL] [Abstract][Full Text] [Related]
31. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
Jia AY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
[No Abstract] [Full Text] [Related]
32. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
Laufer M; Sinibaldi VJ; Carducci MA; Eisenberger MA
Urology; 1999 Oct; 54(4):745. PubMed ID: 10754148
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
Arai Y; Akaza H; Deguchi T; Fujisawa M; Hayashi M; Hirao Y; Kanetake H; Naito S; Namiki M; Tachibana M; Usami M; Ohashi Y
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1385-96. PubMed ID: 18491137
[TBL] [Abstract][Full Text] [Related]
34. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
35. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
36. Serial [
Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
[TBL] [Abstract][Full Text] [Related]
37. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
38. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
39. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
40. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
de la Taille A
World J Urol; 2014 Dec; 32(6):1625-6. PubMed ID: 24413818
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
